Dec 20, 2024 09:15AM
Dec 20, 2024 09:15AM
Sep 11, 2024 09:00AM
Sep 11, 2024 09:00AM
Jul 18, 2024 09:04AM
Jul 18, 2024 09:00AM
Jun 26, 2024 09:01AM Synaptogenix (SNPX) Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1
Jun 26, 2024 09:00AM
May 7, 2024 09:00AM
Apr 24, 2024 09:15AM
Apr 24, 2024 09:15AM
Apr 3, 2024 08:01AM
Apr 3, 2024 08:00AM
Dec 19, 2023 09:00AM Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders
Dec 6, 2023 09:00AM
Nov 2, 2023 09:00AM
Sep 26, 2023 09:02AM
Sep 26, 2023 09:00AM
Sep 7, 2023 09:00AM
Jul 19, 2023 09:00AM
Jul 13, 2023 09:00AM Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience
Mar 7, 2023 09:00AM
Dec 16, 2022 09:01AM
Dec 16, 2022 09:00AM
Nov 18, 2022 09:01AM
Nov 18, 2022 09:00AM
Oct 19, 2022 09:00AM
Sep 28, 2022 11:50AM Synaptogenix Welcomes Lecanemab Phase 3 Trial Results
Aug 12, 2022 09:00AM
Jul 26, 2022 09:15AM
Jul 26, 2022 09:15AM
Jul 20, 2022 09:15AM
May 17, 2022 09:15AM
Apr 19, 2022 09:17AM
Apr 19, 2022 09:15AM Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial
Apr 5, 2022 09:18AM
Apr 5, 2022 09:15AM
Mar 29, 2022 09:15AM
Mar 22, 2022 09:15AM
Mar 15, 2022 09:15AM
Feb 23, 2022 09:15AM
Feb 23, 2022 09:15AM Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis
Feb 1, 2022 09:17AM
Feb 1, 2022 09:15AM
Sep 28, 2021 09:00AM
Sep 10, 2021 09:00AM
Aug 5, 2021 10:00AM
Jul 26, 2021 09:16AM
Jul 26, 2021 09:15AM Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021
Jul 21, 2021 09:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All